PREMIA and Lind Form Lind Asia to Expand AI-Powered Clinical Trial Screening Across Asia-Pacific

 Joint venture combines PREMIA’s regional clinical-genomic infrastructure with Lind’s evidence-driven AI platform to accelerate patient identification for multinational trials 

TAIPEI and SAN MATEO, Calif. – May 27, 2026, Precision Medicine Asia, Limited (PREMIA) and Lind today announced the formation of Lind Asia, a strategic joint venture dedicated to revolutionizing clinical trial enrollment in the Asia-Pacific region.   Read the full story here:

5-27-26 - PREMIA and Lind Form Lind Asia to Expand AI-Powered Clinical Trial Screening Acr.

Download • 321KB